Stockreport

Immunomedics' sacituzumab govitecan shows positive effect in mid-stage TNBC study [Seeking Alpha]

IMMUNOMEDICS  (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
PDF Immunomedics' sacituzumab govitecan shows positive effect in mid-stage TNBC study [Read more]